NO962412D0 - Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som 1-adrenergiske reseptorantagonister - Google Patents

Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som 1-adrenergiske reseptorantagonister

Info

Publication number
NO962412D0
NO962412D0 NO962412A NO962412A NO962412D0 NO 962412 D0 NO962412 D0 NO 962412D0 NO 962412 A NO962412 A NO 962412A NO 962412 A NO962412 A NO 962412A NO 962412 D0 NO962412 D0 NO 962412D0
Authority
NO
Norway
Prior art keywords
intrione
triazindione
indione
tetrahydroquinazoline
pyrimidinedione
Prior art date
Application number
NO962412A
Other languages
English (en)
Other versions
NO962412L (no
NO309424B1 (no
Inventor
Gary W Bantle
Angel Guzman
Francisco J Lopez-Tapia
Arturo Perez-Medrano
Eric Brian Sjogren
Todd Richard Elworthy
Saul Jaime-Figueroa
David John Morgans Jr
Jurg Roland Pfister
Francisco X Talamas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO962412D0 publication Critical patent/NO962412D0/no
Publication of NO962412L publication Critical patent/NO962412L/no
Publication of NO309424B1 publication Critical patent/NO309424B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO962412A 1995-06-09 1996-06-07 Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som <alfa>1-adrenergiske reseptorantagonister NO309424B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48918395A 1995-06-09 1995-06-09

Publications (3)

Publication Number Publication Date
NO962412D0 true NO962412D0 (no) 1996-06-07
NO962412L NO962412L (no) 1996-12-10
NO309424B1 NO309424B1 (no) 2001-01-29

Family

ID=23942748

Family Applications (1)

Application Number Title Priority Date Filing Date
NO962412A NO309424B1 (no) 1995-06-09 1996-06-07 Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som <alfa>1-adrenergiske reseptorantagonister

Country Status (32)

Country Link
EP (1) EP0748800B1 (no)
JP (1) JP2721147B2 (no)
KR (1) KR100446877B1 (no)
CN (1) CN1118459C (no)
AR (1) AR003428A1 (no)
AT (1) ATE201016T1 (no)
AU (1) AU710754B2 (no)
BR (1) BR9602705A (no)
CA (1) CA2178548A1 (no)
CO (1) CO4700472A1 (no)
CZ (1) CZ290004B6 (no)
DE (1) DE69612698T2 (no)
DK (1) DK0748800T3 (no)
ES (1) ES2157366T3 (no)
GR (1) GR3036307T3 (no)
HK (1) HK1013065A1 (no)
HU (1) HU223594B1 (no)
IL (1) IL118519A (no)
MA (1) MA23899A1 (no)
MY (1) MY113499A (no)
NO (1) NO309424B1 (no)
NZ (1) NZ286720A (no)
PE (1) PE46497A1 (no)
PL (1) PL188061B1 (no)
PT (1) PT748800E (no)
RU (1) RU2175322C2 (no)
SA (1) SA96170263B1 (no)
SG (1) SG45486A1 (no)
TR (1) TR970073A2 (no)
TW (1) TW340846B (no)
UY (1) UY24257A1 (no)
ZA (1) ZA964561B (no)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6271234B1 (en) 1997-08-01 2001-08-07 Recordati S.A., Chemical And Pharmaceutical Company 1,4-disubstituted piperazines
CA2681877A1 (en) 1997-10-31 1999-05-14 Asubio Pharma Co., Ltd. Arylpiperidinopropanol and arylpiperazinopropanol derivatives and pharmaceuticals containing the same
US6083950A (en) * 1997-11-13 2000-07-04 Ranbaxy Laboratories Limited 1-(4-arylpiperazin-1-yl)-ω-[n-(α,ω-dicarboximido)]-alka nes useful as uro-selective α1-adrenoceptor blockers
EP0949250B1 (en) * 1998-03-30 2006-05-03 F. Hoffmann-La Roche Ag Process for manufacturing alpha1L-adrenoceptor antagonists
AU1979799A (en) * 1998-07-21 2000-02-14 Ranbaxy Laboratories Limited Arylpiperazine derivatives useful as uro-selective alpha-1-adrenoceptor blockers
MXPA01000637A (es) * 1998-07-21 2002-04-08 Ranbaxy Lab Ltd Derivados de arilpiperazina utiles como bloqueadores uroselectivos de alfa 1-adrenoceptor.
AU1345600A (en) 1998-11-12 2000-06-05 Merck & Co., Inc. Pyrimidinedione derivatives useful as alpha 1a adrenoceptor antagonists
US6358959B1 (en) 1999-01-26 2002-03-19 Merck & Co., Inc. Polyazanaphthalenone derivatives useful as alpha 1a adrenoceptor antagonists
US6387909B1 (en) 1999-07-30 2002-05-14 Recordati S.A. Chemical And Pharmaceutical Company Thienopyranecarboxamide derivatives
US6306861B1 (en) 1999-07-30 2001-10-23 Recordati S.A. Chemical And Pharmaceutical Company Thienopyrancecarboxamide derivatives
GB2355263A (en) 1999-09-30 2001-04-18 Merck & Co Inc Lactam and cyclic urea derivatives useful as alpha 1a adrenoceptor antagonists
GB2355457A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel spirotricyclic substituted azacycloalkane derivatives useful as alpha 1a adrenoceptor antagonists
GB2355264A (en) 1999-09-30 2001-04-18 Merck & Co Inc Spirohydantoin derivatives useful as alpha 1a adrenoceptor antagonists
GB2355456A (en) 1999-09-30 2001-04-25 Merck & Co Inc Novel arylhydantoin derivatives useful as alpha 1a adrenoceptor antagonists
US6365591B1 (en) 1999-10-18 2002-04-02 Recordati, S.A., Chemical And Pharmacueticals Company Isoxazolecarboxamide derivatives
US6403594B1 (en) 1999-10-18 2002-06-11 Recordati, S.A. Chemical And Pharmaceutical Company Benzopyran derivatives
WO2001055119A2 (en) * 2000-01-25 2001-08-02 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
PA8534001A1 (es) * 2000-11-30 2002-12-11 Ranbaxy Lab Ltd Derivados de piperazina 1,4-disustituida utiles como bloqueadores alfa1,-adrenoceptores uro-selectivos
CA2455235A1 (en) 2001-08-02 2003-02-13 Joseph Pontillo 1,2,4-triazin-3,5-diones as gonadotropin-releasing hormone receptor (gnrh) antagonists
DE10311065A1 (de) * 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
AU2004265341A1 (en) 2003-08-13 2005-02-24 Takeda Pharmaceutical Company Limited 4-pyrimidone derivatives and their use as peptidyl peptidase inhibitors
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
GB0400290D0 (en) 2004-01-08 2004-02-11 Medivir Ab dUTPase inhibitors
CN102140090A (zh) 2004-03-15 2011-08-03 武田药品工业株式会社 二肽基肽酶抑制剂
EP1655288A1 (en) * 2004-11-05 2006-05-10 Institut Pasteur Aryl pyrimidyl compounds, pharmaceutical compositions comprising them, their use as antimicrobial agents
CA2591757C (en) 2004-12-20 2014-03-25 Makoto Kotake Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexyl)phenyl]piperazine
EP2805953B1 (en) 2004-12-21 2016-03-09 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006126635A1 (ja) * 2005-05-25 2006-11-30 Eisai R & D Management Co., Ltd. ［２－（３，３，５，５－テトラメチルシクロヘキシル）フェニル］ピペラジン化合物の製造中間体
EP1942898B2 (en) 2005-09-14 2014-05-14 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
KR101368988B1 (ko) * 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 디펩티딜 펩티다제 억제제
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
RU2449994C1 (ru) * 2011-03-10 2012-05-10 Светлана Алексеевна Мещерякова 6-(4-бензилпиперазино)-1,3-диметилурацила дигидрохлорид, проявляющий биологическую активность
PL2685827T3 (pl) * 2011-03-18 2016-07-29 Corcept Therapeutics Inc Pirymidyno-cykloheksylowe modulatory receptora glikokortykoidowego
GB201318886D0 (en) * 2013-10-25 2013-12-11 Givaudan Sa Improvements i or relating to organic compounds
BR112018015389B1 (pt) 2016-03-17 2023-12-19 F. Hoffmann-La Roche Ag Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso
JPWO2021085389A1 (no) * 2019-10-28 2021-05-06
EP4344545A1 (en) * 2021-04-28 2024-04-03 Nippon Soda Co., Ltd. Agricultural and horticultural fungicidal composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2727469A1 (de) * 1977-06-18 1978-12-21 Hoechst Ag Neue hexahydropyrimidine, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
JPH02184667A (ja) * 1989-01-11 1990-07-19 Meiji Seika Kaisha Ltd Ｎ，ｎ’―ジ置換ピペラジル誘導体及びそれを有効成分とする排尿障害改善剤
JPH0344379A (ja) * 1989-07-13 1991-02-26 Yamasa Shoyu Co Ltd Ｎ↑３―ピペラジノウラシル誘導体
JP2814600B2 (ja) * 1989-08-31 1998-10-22 正幸 石川 排尿障害治療剤
EP0558245A1 (en) * 1992-02-25 1993-09-01 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament

Also Published As

Publication number Publication date
BR9602705A (pt) 1998-09-08
ATE201016T1 (de) 2001-05-15
UY24257A1 (es) 2000-12-29
PT748800E (pt) 2001-10-30
AU5469096A (en) 1996-12-19
CO4700472A1 (es) 1998-12-29
IL118519A (en) 1999-12-22
PL188061B1 (pl) 2004-12-31
CZ290004B6 (cs) 2002-05-15
CN1118459C (zh) 2003-08-20
PL314635A1 (en) 1996-12-23
TW340846B (en) 1998-09-21
NZ286720A (en) 1998-08-26
EP0748800B1 (en) 2001-05-09
DE69612698T2 (de) 2001-12-06
KR100446877B1 (ko) 2004-11-06
ES2157366T3 (es) 2001-08-16
SA96170263B1 (ar) 2006-05-23
AU710754B2 (en) 1999-09-30
IL118519A0 (en) 1996-09-12
JP2721147B2 (ja) 1998-03-04
NO962412L (no) 1996-12-10
MY113499A (en) 2002-03-30
HU223594B1 (hu) 2004-09-28
TR970073A2 (tr) 1997-02-21
NO309424B1 (no) 2001-01-29
JPH09100269A (ja) 1997-04-15
HUP9601529A3 (en) 2000-02-28
CZ169696A3 (en) 1997-01-15
RU2175322C2 (ru) 2001-10-27
ZA964561B (en) 1996-12-09
SG45486A1 (en) 1998-01-16
CN1149051A (zh) 1997-05-07
HUP9601529A2 (hu) 1998-09-28
PE46497A1 (es) 1997-12-04
EP0748800A3 (en) 1996-12-27
AR003428A1 (es) 1998-08-05
DK0748800T3 (da) 2001-08-27
DE69612698D1 (de) 2001-06-13
KR970001344A (ko) 1997-01-24
MA23899A1 (fr) 1996-12-31
EP0748800A2 (en) 1996-12-18
GR3036307T3 (en) 2001-10-31
HK1013065A1 (en) 1999-08-13
CA2178548A1 (en) 1996-12-10
HU9601529D0 (en) 1996-07-29

Similar Documents

Publication Publication Date Title
NO962412L (no) Pyrimidindion-, pyrimidintrion-, triazindion-, tetrahydrokinazolindionderivater som 1-adrenergiske reseptorantagonister
DK0856001T3 (da) Pyrimidinderivater som 5-HT2C-receptor-antagonister
NO996178D0 (no) 4-aminopyrrol(3,2-d)pyrimidiner som neuropeptid y- reseptorantagonister
NO985225L (no) Indolderivater nyttige som endotelinreseptorantagonister
DK1224175T3 (da) Benzodiazepinderivater som metabotropiske glutamatreceptorantagonister
AU5640299A (en) 4-quinolinemethanol derivatives as purine receptor antagonists.(ii)
TR199600212A2 (tr) Endotelin-reseptörü-antagonistleri.
PT891978E (pt) Derivados de 5h-tiazolo (3,2-a) pirimidina
AU5640199A (en) 4-quinolinemethanol derivatives as purine receptor antagonists (i)
ATE404562T1 (de) Substituierte purinderivate als vitronectinrezeptor-antagonisten
NO991079L (no) Azinyloksy- og fenoksy-diaryl-karboksylsyre-derivater, deres fremstilling og deres anvendelse som blandede ETA/ETB-endotelin-reseptor-antagonister
DK0912556T3 (da) Indolinderivater, der er anvendelige som 5-HT-2C-receptorantagonister
NO972612D0 (no) Pyridazoner som endotelinreseptorantagonister
FI951798A0 (fi) Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina
DK1185525T3 (da) 4-heterocyclylsulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidinderivater, fremstilling deraf samt anvendelse deraf som endothelinreceptorantagonister
NZ315846A (en) Endothelin receptor antagonists, in particular, substituted pyrazol-4-yl-substituted-prop-2-enoic acid derivatives
NO985972D0 (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
NO974205L (no) Heterocyklisk-substituerte piperazinonderivater som tachykininreceptor-antagonister
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
ATE310732T1 (de) 7-phenyl-1,4-diazepanderivate als neurokininrezeptorantagonisten
ATE241618T1 (de) Substituierte 2,4-diaminopyrimidine
FI941117A (fi) Bentsyyli-imidatsopyridiinijohdannaiset angiotensiini II reseptoriantagonisteina
SI0856001T1 (en) Pyrimidine derivatives as 5ht2c receptor antagonists